| 1.55 0.07 (4.73%) | 10-15 12:12 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.26 |
1-year : | 2.64 |
| Resists | First : | 1.94 |
Second : | 2.26 |
| Pivot price | 1.49 |
|||
| Supports | First : | 1.45 |
Second : | 1.14 |
| MAs | MA(5) : | 1.57  |
MA(20) : | 1.47 |
| MA(100) : | 0.99 |
MA(250) : | 1.95 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 35.7 |
D(3) : | 44.4 |
| RSI | RSI(14): 56 |
|||
| 52-week | High : | 5.13 | Low : | 0.52 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IRWD ] has closed below upper band by 38.9%. Bollinger Bands are 60.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.52 - 1.53 | 1.53 - 1.54 |
| Low: | 1.39 - 1.4 | 1.4 - 1.41 |
| Close: | 1.47 - 1.48 | 1.48 - 1.49 |
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Wed, 15 Oct 2025
Teladoc Health Expands Clarity Platform With Workplace Safety Tool - TradingView
Tue, 14 Oct 2025
Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Tue, 14 Oct 2025
Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term - Nasdaq
Sat, 11 Oct 2025
Ironwood Pharmaceuticals director Andrew Dreyfus to resign effective November 1 By Investing.com - Investing.com Australia
Fri, 03 Oct 2025
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Wed, 03 Sep 2025
Ironwood Pharma Regains Nasdaq Compliance - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 162 (M) |
| Shares Float | 118 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 97.8 (%) |
| Shares Short | 5,170 (K) |
| Shares Short P.Month | 6,060 (K) |
| EPS | -0.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.9 |
| Profit Margin | -2.6 % |
| Operating Margin | 52.8 % |
| Return on Assets (ttm) | 15.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -9.7 % |
| Gross Profit (p.s.) | 1.88 |
| Sales Per Share | 1.89 |
| EBITDA (p.s.) | 0.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 30 (M) |
| Levered Free Cash Flow | 22 (M) |
| PE Ratio | -31 |
| PEG Ratio | 0 |
| Price to Book value | -0.82 |
| Price to Sales | 0.81 |
| Price to Cash Flow | 8.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|